TABLE 4.
The effect of different doses of either CPA or CPX on the average latency of neurological symptoms, degree of neurological impairment, and mortality caused by i.p. administration of NMDA.
| Dose mg/kg |
Latency (s) | P | Impairment | P | T/death (h) | P |
|---|---|---|---|---|---|---|
| 30.0 NMDA | 542±97 | 1.9±0.8 | n.s. | 4.7 ±0.3 | ||
| 1.0 CPA ±30.0 NMDA | < 900 | < 0.05 | 1.0 ± 0.0 | n.s. | > 5 | n.s |
| 1.0 CPX ± 30.0 NMDA | 538 ±44 | n.s | 1.7 ± 0.1 | < 0.05 | > 5 | n.s. |
| 2.0 CPX ± 30.0 NMDA | 406 ± 66 | < 0.05 | 3.0 ± 0.8 | < 0.05 | > 5 | n.s. |
| 60.0 NMDA | 414±58 | 6.2±0.8 | 2.7 ±0.8 | |||
| 0.5 CPA ±60.0 NMDA | 467 ±51 | n.s. | 5.3 ± 1.1 | n.s. | 2.5 ± 0.6 | n.s. |
| 1.0 CPA± 60.0 NMDA | > 900 | < 0.05 | 2.1 ±0.6 | < 0.05 | 4.7 ±0.6 | < 0.05 |
| 1.0 CPX±60.0 NMDA | 249±54 | < 0.05 | 10.3±0.8 | < 0.05 | 2.0 ±0.7 | n.s |
| 2.0 CPX±60.0 NMDA | 138±28 | < 0.05 | 11.3±0.6 | < 0.05 | 0.8 ±0.4 | < 0.05 |
| 125.0 NMDA | 71 ± 5 | 11.5 ± 0.4 | < 0.05 | 0.68 ± 0.5 | ||
| 2.0 CPA ± 125.0 NMDA | 541 ± 47 | < 0.05 | 3.1 ±0.7 | < 0.05 | 3.65 ±0.7 | < 0.05 |
Values are mean ± S.E.M.
Latency: delay (s) to the first observable behavioral (seizure) symptoms. T/death: time to death (h).
P: Bonferroni’s corrected Student’s t-test, n = 20/group.